Rupert Haynes

CEO at Avata Biosciences

Presenter

Rupert is the CEO of Avata Biosciences, developing AVAT-021, a treatment for adult focal seizures. Avata has achieved positive comparative results against Epidiolex, gained FDA support for the 505(b)(2) pathway, and formed a partnership with Oxford University to develop treatments for Schizophrenia. Before Avata, Rupert held senior positions at Radius Health, Benuvia Therapeutics, GW Pharmaceuticals, Sobi, UCB Pharma, and Bristol-Myers Squibb, demonstrating extensive experience in strategic planning, marketing, clinical development, global commercial operations, manufacturing and drug development in the pharmaceutical industry.